779 results on '"Bonneterre J"'
Search Results
2. Phyllodes tumours of the breast
3. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
4. Métastase osseuse solitaire : existe-t-il une prise en charge spécifique ?
5. Analysis of Arrestin Recruitment to Chemokine Receptors by Bioluminescence Resonance Energy Transfer
6. O.38 - Ostéonécrose des maxillaires : 100 cas, 10 ans d’expérience
7. O.36 - Rentabilité de la ponction-biopsie percutanée dans le diagnostic des lésions osseuses suspectes de malignité
8. Third consensus on medical treatment of metastatic breast cancer
9. Les recommandations nationales françaises de prise en charge du cancer du sein infiltrant: Onze questions cliniques d’actualité sur le bilan initial, la radiothérapie et les traitements systémiques
10. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer
11. De l’information au consentement « éclairé » chez le patient atteint de cancer et présentant une pathologie mentale
12. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
13. Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients
14. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
15. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study
16. Thérapies ciblées et radiations ionisantes
17. Hyperplasie canalaire atypique diagnostiquée sur macrobiopsie : à propos d’une série rétrospective au Centre Oscar Lambret de Lille
18. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer
19. Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer
20. Surveillance, à la recherche des métastases : trop ou pas assez?
21. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
22. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results
23. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials
24. Phyllodes tumours of the breast
25. The sequential use of endocrine treatment for advanced breast cancer: where are we?
26. Is adjuvant chemotherapy useful in lobular breast cancer patients?
27. Silent hereditary hematochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failure
28. Return to work after treatment for breast cancer: single-center experience in a cohort of 273 patients
29. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
30. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients
31. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study)
32. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy
33. Le ganglion sentinelle sans curage systématique dans le cancer du sein : bilan d'une expérience de 1000 interventions
34. Second consensus on medical treatment of metastatic breast cancer
35. Reply to the article “A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis”, by J. Norum et al. (Ann Oncol 2005; 16: 909–914)
36. Type 1 IGF receptor in human breast diseases
37. Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
38. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC)
39. A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer
40. Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer?
41. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
42. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
43. Essai de phase III randomisé comparant la fotémustine seule ou associée à une irradiation encéphalique dans les métastases cérébrales de mélanome †
44. Thérapie génique du mélanome : synthèse des études cliniques publiées
45. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
46. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients
47. Anastrozole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women: Findings highlight the importance of receptor status assessment prior to treatment initiation.
48. OS10.4 Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for leptomeningeal metastasis from breast cancer - a randomized study. Final results
49. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
50. Abstract P1-11-06: Systematic evaluation of ovarian reserve in young breast cancer patients treated by sequential chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.